Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30068572 | 0.86 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL2377487 | 0.86 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL27193529 | 0.85 | DGAT1 (0.47) | DGAT1 | |
| SCHEMBL29488914 | 0.85 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL2357911 | 0.85 | DGAT1 (0.45) | DGAT1 | |
| SCHEMBL2377222 | 0.85 | DGAT1 (0.38) | DGAT1MAPT | |
| SCHEMBL25297250 | 0.83 | DGAT1 (0.54) | DGAT1 | |
| SCHEMBL1350460 | 0.82 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL29489019 | 0.82 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL12333067 | 0.82 | DGAT1 (0.43) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102232076-A | Pyrrolopyrazinyl urea kinase inhibitors | HOFFMANN LA ROCHE | 2011-11-02 | — | — | CN | disclosed |
| EP-2373653-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-8012974-B2 | Pyrrolopyrazinyl urea kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | DGAT1 4356/4885MAPT 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.